Navigation Links
Archimedes Pharma Launches Lazanda® - the Only Fentanyl Nasal Spray for the Management of Breakthrough Pain in Cancer in the U.S.
Date:10/17/2011

e only through a restricted program, required by the Food and Drug Administration, called the Lazanda REMS® (Risk Evaluation and Mitigation Strategy) program.  Under the Lazanda® REMS program, healthcare professionals who prescribe to outpatients, pharmacies, and distributors must enroll in the program to prescribe, receive, dispense, and distribute Lazanda, respectively. [see Warnings and Precautions].  Further information is available at www.LazandaREMS.com or by calling 1-855-841-4234.Contraindications

  • Lazanda is contraindicated in the management of pain in opioid non-tolerant patients, because life-threatening hypoventilation could occur at any dose in patients not already taking around-the-clock opioid therapy.
  • Lazanda is contraindicated in the management of acute or postoperative pain, including headache/migraine, dental pain, or use in the emergency room.
  • Lazanda is contraindicated in patients with known intolerance or hypersensitivity to any of its components or the drug fentanyl. Anaphylaxis and hypersensitivity have been reported in association with the use of other oral transmucosal fentanyl products.

  • Warnings And Precautions

  • Patients must not be converted to Lazanda from other fentanyl products because it is not equivalent to other fentanyl products on a mcg per mcg basis, and such substitution could result in a fatal overdose; do not substitute Lazanda for another fentanyl product when being dispensed.
  • Serious or fatal respiratory depression can occur even at recommended doses in patients using Lazanda. Respiratory depression is more likely to occur in patients with underlying respiratory disorders and elderly or debilitated patients, in opioid non-tolerant patients, or when opioids are given in conjunction with other drugs that depress respiration.
  • Lazanda could be fatal to individuals for whom it is not pres
    '/>"/>

  • SOURCE Archimedes Pharma Ltd.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. Archimedes Pharma Announces Publication of Long-Term Safety and Tolerability Clinical Study of Fentanyl Pectin Nasal Spray (FPNS) in the Journal of Opioid Management
    2. Archimedes Pharma Announces Publication of a Pivotal Clinical Study of Fentanyl Pectin Nasal Spray (FPNS) in Pain, the Peer-Reviewed Journal from the International Association for the Study of Pain
    3. Archimedes Pharma Receives CHMP Positive Opinion for PecFent(R) for the Treatment of Breakthrough Cancer Pain
    4. Archimedes Pharma Announces Successful Proof-of-Concept Results on Two Intranasal Development Projects
    5. Novo Nordisk A/S: PharmaVitae Profile
    6. Auxilium Pharmaceuticals to Announce Third Quarter 2011 Results and Conduct Conference Call on Monday, October 31, 2011
    7. Par Pharmaceutical Files Declaratory Judgment to Protect First Amendment Rights to Disseminate Truthful Information Regarding Megace® ES
    8. Reata Pharmaceuticals Adds Executives to Management Team and Board of Directors
    9. Access Pharmaceuticals Updates MuGard Website with New Video Featuring Clinical Feedback and Manufacturing Footage
    10. CVS/pharmacy Ready to Provide Assistance During Medicare Part D Annual Enrollment Period
    11. ShangPharma Corporation Announces Shareholder Resolutions Adopted at 2011 Annual General Meeting
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2015)... SAN DIEGO , July 29, 2015 /PRNewswire/ ... Thursday, July 23, called the Alvarado Spine & ... orthopedic surgery and rehabilitation, focusing on spinal surgery ... method of patient care takes a patient experience-focused ... whatever clothing they feel comfortable in, rather than ...
    (Date:7/29/2015)... FOREST, Calif. , July 29, 2015 ... ("Cryoport" or the "Company"), the leading provider ... life sciences industry, serving markets including immunotherapies, ... vaccine manufacturers, animal health, and reproductive medicine, ... the sale of common stock and warrants (the ...
    (Date:7/29/2015)... 29, 2015  Ortho-Clinical Diagnostics, Inc. (OCD) today announced ... The assays address a range of important tests for ... troponin I. The scientific posters will be delivered during ... to be held July 26 - 30 in ... Clinical Diagnostics is emerging stronger than ever since becoming ...
    Breaking Medicine Technology:The Alvarado Spine & Joint Institute Opens July 30 in San Diego 2Cryoport Completes $6.8 Million Equity Capital Raise 2Cryoport Completes $6.8 Million Equity Capital Raise 3Ortho-Clinical Diagnostics, Inc. Presents Data On Five Assays In Development At American Association For Clinical Chemistry Annual Meeting 2Ortho-Clinical Diagnostics, Inc. Presents Data On Five Assays In Development At American Association For Clinical Chemistry Annual Meeting 3
    ... Texas--(BUSINESS WIRE)--Apr 3, 2007 - Repros,Therapeutics Inc. (NasdaqGM:RPRX) ... of Proellex(TM), an oral drug being developed to,relieve ... with Proellex results in a statistically highly,significant improvement ... well tolerated., Study Details and Results , This ...
    ... Arrowhead Research,Corporation (NASDAQ: ARWR) announced the publication ... a study,demonstrating the anti-proliferative effect of the ... its lead anti-cancer,compound, CALAA-01., The paper, entitled ... Reduce Cell Proliferation In vitro and In,vivo", ...
    Cached Medicine Technology:Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 2Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 3Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 4Repros' Proellex Shows Statistically Significant Improvement in,Primary Endpoint in Phase 2 Trial in the Treatment of Uterine,Fibroids 5Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study,Showing Anti-Cancer Effect with Lead RNAi Candidate 2Arrowhead Subsidiary Calando Pharmaceuticals Publishes Study,Showing Anti-Cancer Effect with Lead RNAi Candidate 3
    (Date:7/29/2015)... ... ... According to the The Media Post on July 9th teenagers ... medicinal use are more likely to abuse the substance. A recent study conducted by ... beneficial are more apt to use the substance, as opposed to their peers who ...
    (Date:7/29/2015)... ... July 29, 2015 , ... ... therapeutic development for Atherosclerosis. Atherosclerosis is a slow, progressive disease that may start ... to produce first-in-class and best-in-class products. Complete report on Atherosclerosis Pipeline with 78 ...
    (Date:7/29/2015)... ... July 29, 2015 , ... The NCCA re-accredited the Commission ... November 30, 2019, during its recent meeting. , The Commission received renewal of ... compliance with the NCCA’s Standards for the Accreditation of Certification Programs. NCCA ...
    (Date:7/29/2015)... ... July 29, 2015 , ... ... changed its name in July to Kalamazoo Strength & Conditioning. , The name ... and “reflects the evolution of our training center over the past three years,” ...
    (Date:7/29/2015)... ... , ... Today marks a significant achievement in bringing new monies into early ... led by a group of experienced investors, has tapped into an investor community passionate ... be a part of the fund. The Sofia Fund II is now closed ...
    Breaking Medicine News(10 mins):Health News:New Study Reveals Teens Use Marijuana More in States Where Marijuana Is Legalized 2Health News:New Study Reveals Teens Use Marijuana More in States Where Marijuana Is Legalized 3Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Atherosclerosis Pipeline Assessment Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:Commission for Case Manager Certification Receives Re-Accreditation of its CCM® credential from the National Commission for Certifying Agencies (NCCA) 2Health News:Commission for Case Manager Certification Receives Re-Accreditation of its CCM® credential from the National Commission for Certifying Agencies (NCCA) 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 2Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 3Health News:Kalamazoo’s CrossFit 269 Changes Name, Opens New Website 4Health News:Sofia Fund Surpasses Investor Goals 2
    ... published the first comprehensive review of evidence on pneumococcal ... available in the on-line edition of the journal Lancet ... risk of pneumococcal infection by up to 40 fold, ... the PCV, and that the vaccine can protect HIV-infected ...
    ... San Diego have developed a novel computer technique to ... study, reported November 30 in PLoS Computational Biology relates ... Receptor Modulators (SERMs), which includes tamoxifen, the most prescribed ... side effects account for one-third of all drug development ...
    ... President of International Operations, MONROVIA, Calif., Nov. ... a leading developer, manufacturer and marketer of,minimally invasive ... has been named President and Chief Executive Officer. ... the annual shareholder,s,meeting in May 2007, replaces David ...
    ... Nov. 28 Novant Health(R) today announced ... leader,in developing and manufacturing medical devices for ... implement the Cardiocom System in its,Presbyterian Heart ... Hospital is one of the largest healthcare ...
    ... ASHBURN, Va., Nov. 28 Innocoll, Inc. announced ... that pursuant to,Rule 51(4) EPC, the European Patent ... applications which are both based on its proprietary,CollaRx ... Treatment of,Wounds" and Patent No. 1265648 entitled "Novel ...
    ... Corporation,("Sosei"; TSE Mothers Index: 4565), a biopharmaceutical company, ... UK Medicines and,Healthcare products Regulatory Agency (MHRA) for ... sublingual spray (AD 923), an opioid,analgesic for the ... trial authorisation (CTA) covers two multi-centre pivotal,Phase III ...
    Cached Medicine News:Health News:Pneumococcal conjugate vaccines can improve the lives of HIV-infected children 2Health News:Barry G. Caldwell Named Chief Executive Officer of STAAR Surgical 2Health News:Barry G. Caldwell Named Chief Executive Officer of STAAR Surgical 3Health News:Barry G. Caldwell Named Chief Executive Officer of STAAR Surgical 4Health News:Barry G. Caldwell Named Chief Executive Officer of STAAR Surgical 5Health News:Barry G. Caldwell Named Chief Executive Officer of STAAR Surgical 6Health News:Novant Health(R) Selects Cardiocom(R) to Provide Telemonitoring for Presbyterian Hospital Heart Failure Program 2Health News:Innocoll Receives 'Intends to Grant' Notices from the European Patent Office for Two European Patent Applications Related to Novel Wound Healing, Biosurgery and Drug Delivery Applications of its CollaRx(R) Technology 2Health News:Innocoll Receives 'Intends to Grant' Notices from the European Patent Office for Two European Patent Applications Related to Novel Wound Healing, Biosurgery and Drug Delivery Applications of its CollaRx(R) Technology 3Health News:Innocoll Receives 'Intends to Grant' Notices from the European Patent Office for Two European Patent Applications Related to Novel Wound Healing, Biosurgery and Drug Delivery Applications of its CollaRx(R) Technology 4Health News:Sosei Announces Approval to Start AD 923 Phase III Studies in Europe 2
    ... Health Record (EHR/EMR) and ... Specialties that we currently ... Cardiology, Dermatology, Family Medicine, ... Neurosurgery, Obstetrics and Gynecology, ...
    ... Software developed a touchscreen EHR and is ... a user can choose to use a ... maintain eye contact while recording encounter results. ... EHR also runs on a pen tablet ...
    Dairylands Health Information Management solutions provides healthcare organizations a suite of integrated applications for managing patient records, optimizing reimbursement and regulatory complianc...
    ... WEBeDoctor® Physician-office® is ... for physicians, (Solo practice, ... care), to complete their ... practice. It is a ...
    Medicine Products: